Cover Image


Opioids Market Overview to 2023 - Opioids in Western Europe

出版商 CBR Pharma Insights 商品編碼 318490
出版日期 內容資訊 英文 74 Pages
Back to Top
Opioids(類鴉片物質)市場未來展望:西歐的Opioids(類鴉片物質)市場 Opioids Market Overview to 2023 - Opioids in Western Europe
出版日期: 2014年10月31日 內容資訊: 英文 74 Pages







  • 疼痛管理上的Opioids(類鴉片物質)
  • 使用限制
  • 國際會議


  • 藥物誤用展開
  • 濫用抑製藥的影響
  • 主要的濫用抑制產品


  • 必要條件與消費趨勢
  • 利用促進的主要活動


  • 可得性和使用法規之間的平衡


  • 歐洲域內的消費趨勢
  • 市場收益額的估計值·預測值


  • 法規形勢
  • 消費趨勢
  • 需求數量·銷售量(以數量為準)
  • 針對法規和使用正當化的活動


  • 主要的全球性品牌
  • 新的濫用抑制技術
  • 開發中產品
  • 市場新的趨勢
  • 企業整合策略


  • 簡稱/大寫字母集
  • 參考資料
Product Code: GBI053CBR


The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%).

Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes. Amidst concerns regarding inadequate pain management due to low accessibility, there are also concerns regarding a lack of significant clinical evidence of their role in managing chronic pain. However, new abuse-deterrent technologies provide an incentive to prescribe more opioids in pain management by alleviating concerns over misuse potential. The approval of such new drugs and formulations has proved a new impetus to growth in opioid usage in the five major Western European countries.

Opioids are largely used for two medicinal purposes: pain management and substitution treatment for drug dependence. Several of the recently approved and pipeline opioid analgesics have a strong focus on reducing misuse potential, which is one of the most significant barriers to usage in pain management. However, usage is on the rise following the introduction of new abuse-deterrent formulations of fentanyl and oxycodone, and initiatives that aim to rationalize usage in pain management. Demand is also high in substitution treatment. While both methadone and buprenorphine are approved for substitute treatment, buprenorphine usage increased in Europe after the approval of Suboxone in 2006, in combination with naloxone, a pure opioid antagonist that acts as an abuse-deterrent.


The report covers the five major Western European countries (the UK, Germany, France, Italy and Spain) and includes -

  • An overview of opioids in pain management and substitution treatment, and usage constraints for both
  • Brief analysis of recent approvals of key abuse-deterrent drugs and their impact on consumption and market growth
  • Country snapshots, comprising key regulations, consumption, market revenues, market forecasts and key drivers and barriers
  • An overview of new abuse-deterrent technologies and profiles of key pipeline products

Key Reasons to Purchase

  • Gain a perspective of the opioids market size and key drivers and challenges that dictate the market trends in each of the five major countries in Western Europe
  • Gauge the impact of key recently approved abuse-deterrent technologies on opioid usage
  • Develop an understanding of how the regulatory landscape affects market potential and growth in each country
  • Identify the key molecules that are currently the leading players in each region and those that hold the highest potential in the forecast period
  • Scan the pipeline for innovative products with abuse-deterrent technologies that could have an impact on opioid usage in the pain management market

Table of Contents

  • Executive summary
  • Opioids: an overview
    • Opioids in pain management
    • Usage constraints
    • International conventions
  • Drug misuse in Western Europe
    • Extent of drug misuse
    • Impact of abuse-deterrent drugs
    • Key abuse-deterrent products
  • Unmet need in pain management
    • Requirement and consumption
    • Key activities to promote usage
  • Regulatory landscape
    • Finding a balance between accessibility and regulations
  • Opioids market in Europe
    • Consumption trends in Europe
    • Estimated revenue and forecast
  • Country snapshots (UK, Germany, France, Italy, Spain)
    • Regulatory landscape
    • Consumption trends
    • Volume and revenue by molecule
    • Barriers and activities to rationalize usage
  • Market developments
    • Leading global brands
    • New abuse-deterrent technologies
    • Pipeline products
    • New developments
    • Strategic consolidations
  • Appendix
    • Abbreviations/acronyms
    • References
Back to Top